can-21-4222_dataset_s6_suppsds6.xlsx (26.16 kB)

Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

Name: Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
Published: 2023-03-31T05:21:26+00:00
License: https://creativecommons.org/licenses/by/4.0/
Keywords: cancer

dataset

posted on 2023-03-31, 05:21 authored by Russell Moser, James Annis, Olga Nikolova, Cliff Whatcott, Kay Gurley, Eduardo Mendez, Kim Moran-Jones, Craig Dorrell, Rosalie C. Sears, Calvin Kuo, Haiyong Han, Andrew Biankin, Carla Grandori, Daniel D. Von Hoff, Christopher J. Kemp

Funding

Canary Foundation, Listwin Foundation, and Gregory Fund

Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research

History

ARTICLE ABSTRACT

This study utilizes functional genetic and pharmacological profiling of KRAS-mutant pancreatic adenocarcinoma to identify therapeutic strategies and finds that TFIIH inhibition synergizes with TRAIL to induce apoptosis in KRAS-driven pancreatic cancer.

Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

Funding

Canary Foundation, Listwin Foundation, and Gregory Fund

Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports